NCT01783925View on ClinicalTrials.gov

Eylea Post Marketing Surveillance(PMS)

CompletedOBSERVATIONAL
Enrollment

3,206

Participants

Timeline

Start Date

April 29, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY

NCT01783925 - Eylea Post Marketing Surveillance(PMS) | Biotech Hunter | Biotech Hunter